Staphylococcus aureus is a Gram-positive, nonmotile, coagulase-positive coccoid bacterium of the Firmicutes phylum. Although the Staphylococcus genus includes 52 species and 28 subspecies (List of Prokaryotic names with Standing in Nomenclature), S. aureus is by far the most clinically relevant. S. aureus is found in the human commensal microbiota of the nasal mucosa in 20-40% of the general population 1, 2 . The reported prevalence varies owing to differences in the size and demographics of the study populations, quality of sampling and culture techniques utilized 3 . When the cutaneous and mucosal barriers are disrupted, for example, owing to chronic skin conditions, wounds or surgical intervention, S. aureus can gain access to the underlying tissues or the bloodstream and cause infection. Persons with invasive medical devices (such as peripheral and central venous catheters) or compromised immune systems are particularly vulnerable to S. aureus infection 4 . Methicillin-resistant S. aureus (MRSA) was first described in England in 1961 (REF.
5
), soon after methicillin was introduced into clinical practice. Methicillin was initially widely used; however, because of its toxicity, it is now no longer marketed for human use and has largely been replaced by similar, more-stable penicillins such as oxacillin, flucloxacillin and dicloxacillin 6 . Nevertheless, the term methicillin-resistant S. aureus continues to be used. In the decade following its initial description, MRSA was responsible for hospital outbreaks (health-care-associated MRSA (HA-MRSA)) in many parts of the world 7 . A substantial change in MRSA epidemiology was observed when it was detected in individuals without previous health-care contact (referred to as community-associated MRSA (CA-MRSA)), notably among indigenous populations in Australia in the 1980s 8 and otherwise healthy persons, including children, in the United States in the 1990s 9 . Since the mid-2000s, it has also been associated with livestock exposure (livestock-associated MRSA (LA-MRSA)) 10 . Several S. aureus clones (that is, bacteria that are indistinguishable from each other by a variety of genetic tests (for example, pulsed-field gel electro phoresis, multi locus enzyme electrophoresis or ribotyping) or that are so similar that they are presumed to be derived from a common parent 11 ) have developed into MRSA by uptake via horizontal gene transfer of staphylococcal cassette chromosome mec (SCCmec) , which has major implications for current as well as future treatment options for this pathogen.
Individuals with MRSA colonization or carriage (that is, the presence of bacteria that do not cause a detectable host immune response, cellular damage or clinical signs and symptoms of infection) have an increased risk of subsequent infection and are an important source of person-to-person transmission. Health-care facilities host persons who are predisposed to infection (for example, owing to invasive procedures and/or immune compromise) and are environments with high antibiotic selection pressure (which can contribute to the selection of antimicrobial resistance in bacteria) and frequent contact between individuals. These conditions have facilitated the epidemic spread of MRSA in hospitals; MRSA is now endemic in many health-care facilities throughout the world and, as a consequence, it has become a major focus for infection control efforts globally.
This Primer reviews the epidemiology, pathophysiology, diagnosis, prevention, management and clinical effect of MRSA, focusing on HA-MRSA, and discusses future research priorities. In some aspects of the epidemiology and pathophysiology, where methicillin resistance does not substantially affect the behaviour of the species, data regarding S. aureus in general have also been included.
Epidemiology
The emergence and worldwide spread of MRSA represent some of the most important events in the epidemiology of infectious diseases. Although MRSA was first reported in the early 1960s 5 , whole-genome sequencing (WGS) of 209 early MRSA isolates suggests that MRSA emerged in the mid-1940s -that is, much earlier than the introduction of methicillin 13 . In fact, it has been hypothesized that it was the extensive use of penicillin rather than the introduction of methicillin that drove the emergence of MRSA 13 .
Many countries have experienced an increasing burden of MRSA since the 1960s. The burden of MRSA has notable geographical variation, ranging from low prevalence in Scandinavia to the highest prevalence in parts of America and Asia 14 (FIG. 1) . The spread of MRSA seems to occur by at least two mechanisms: spread of existing resistant clones and acquisition of SCCmec by a methicillin-sensitive S. aureus (MSSA) strain (a strain is a descriptive subdivision of a species based on phenotypic and/or genotypic characteristics 11 ). Details of the mechanism of horizontal transfer of SCCmec are not well understood, but epidemiological evidence shows that this resistance mechanism has spread to most clones of S. aureus, in both human and animal pathogenic strains 15, 16 . The following sections discuss the epidemiology of MRSA in different regions; in general, less comprehensive data are available from low-income and middle-income countries.
MRSA in Europe
Surveillance data from European countries show a general trend towards increasing MRSA prevalence from the north to the south of the continent, with <5% of S. aureus isolated from invasive infections being methicillin-resistant in northern Europe (for example, the Netherlands, Norway, Sweden and Denmark) compared with 25-50% in southern Europe (for example, Portugal, Spain, Italy and Greece) 17 (FIG. 2) . Varying infection control practices and antimicrobial usage are thought to contribute to the observed differences 18 . After years of increasing MRSA prevalence, since the early 2000s, steady or decreasing prevalence has been observed in a number of countries 17 (FIG. 2) . This decline has been associated with the implementation of improved national control interventions. However, some experts argue that widespread declines in previously hyperendemic MRSA clones are attributable to changes in the organism itself, with loss in survival fitness resulting in shifts in circulating clones 19, 20 . With the declines largely occurring in HA-MRSA, there has been increasing recognition of animal reservoirs for human MRSA in Europe, particularly from food-producing animals such as pigs, cattle and poultry 21 . This LA-MRSA, predominantly belonging to clonal complex 398 (CC398), has primarily caused infections in those who work with livestock (particularly in the Netherlands, northwestern Germany 22 and Spain 23 ), but LA-MRSA infections have also been observed among the general population 24, 25 . However, at present, sustained person-to-person transmission of LA-MRSA seems to be uncommon 25, 26 .
MRSA in America
In the United States, ~53% of S. aureus clinical isolates were methicillin-resistant in 2005 (REF.
27
). MRSA has also been identified as the most common cause of skin and soft tissue infections (SSTIs) presenting to US hospital emergency departments, which is largely attributed to the emergence of CA-MRSA (particularly the USA300 clone in the early 2000s) 28, 29 (FIG. 3) . The changes in epidemiology since the emergence of CA-MRSA in the country have made the distinction between CA-MRSA and HA-MRSA less clear 30, 31 . A parallel epidemic of CA-MRSA closely related to USA300, the USA300 Latin-American variant (USA300-LV), was first identified in Colombia in 2005 and has emerged as the most prevalent CA-MRSA clone in northern South America 32 . The geographical spread of USA300 clones from South America to Europe has also been documented by genomic analysis of MRSA isolates in Switzerland 33 . Similar to experiences in Europe, the incidence of HA-MRSA in the United States has shown decreasing trends since 2005, with hospital-onset HA-MRSA infections decreasing by 54% 34 . In 2007, Veterans Affairs Hospitals throughout the United States introduced a multifaceted prevention strategy including universal MRSA screening, contact precautions, hand hygiene promotion and institutional culture change 35 . This programme was associated with a significant reduction in MRSA infections by 62% in intensive care units (ICUs) and 45% in other hospital wards. In addition, many US states mandated specific MRSA control measures, and in 2008, the Centers for Medicare and Medicaid Services introduced financial penalties to hospitals for preventable health-care-acquired infections, although a large evaluation of this intervention showed no evidence that it was associated with a reduction in health-care-associated infections 36 .
MRSA in the Asia-Pacific region
MRSA is endemic in most hospitals in Asia, and some Asian countries have among the highest MRSA prevalence in the world 37 . However, most available data are from high-income countries (for example, Japan, South Korea and Singapore), with limited information from other nations. Although there is country-to-country vari ability, MRSA accounts for up to 50% of S. aureus bloodstream infections in parts of Asia 37 . Japan and South Korea have particularly high MRSA prevalence -with >70% of clinical isolates in South Korea being MRSA on the basis of regional surveillance data from 2011 (REFS 37, 38 ). High methicillin resistance rates are thought to be related to widespread inappropriate antimicrobial use (for example, self-medication and over-the-counter use) as well as high population density facilitating rapid transmission of multidrugresistant organisms 37 . 42 .
MRSA in Africa
MRSA prevalence data from Africa are variable in coverage and quality. Published data are available for South Africa, Nigeria and countries from the Mediterranean basin, but there is a paucity of data from other nations 43 . Most data are also from single-centre studies, and information from broader surveillance systems is lacking. In addition, most studies have relied on phenotypic methods to identify MRSA, and these tests might be less reliable than genotypic methods depending on the choice of antibiotic used to detect MRSA 43 . MRSA prevalence is estimated at <50% in most countries, with several countries reporting prevalence of <25% 43 . However, MRSA prevalence has been increasing since the early 2000s in reports from most countries, although it has started to decrease in South Africa (from 36% in 2006 (REF.
44
) to 24% during 2007-2011 (REF.
45
)) 43 .
Differences in the availability and use of antimicrobials, incidence of HIV infection (a risk factor for MRSA colonization 46 ) and infection control practices could potentially account for some of the variation between countries.
Mechanisms/pathophysiology
Staphylococcus aureus colonization S. aureus colonization precedes the development of infection in most cases 47 . Less commonly, infection can occur in the absence of known S. aureus colonization, for example, as a result of contamination of catheters or wounds owing to suboptimal infection control practices by health-care workers. The principal site of S. aureus colonization is the nose, although colonization at other sites occurs, notably in the throat and perineum 48 . Longitudinal studies have identified three temporal patterns of S. aureus (including both MSSA and MRSA) colonization 49 . Continuous S. aureus colonization was found in ~15% of individuals (known as persistent carriers), intermittent colonization was present in 70% of individuals (which means that the majority of individuals can repeatedly acquire S. aureus and spontaneously clear it), and S. aureus was never detected in 15% of individuals (referred to as non-carriers) 49 . Similar results were found by other studies 50 . Studies exploring specific host polymorphisms in genes involved in the inflammatory response 51 indicate that there are underlying host factors that determine the carriage status. However, the precise nature of these underlying factors is not completely understood. For MRSA in particular, the duration of colonization is variable, and reported estimates could be biased by antibiotic treatment, which can shorten the duration of colonization. In one study in patients with MRSA colonization at the time of hospital discharge 52 , the median duration of colonization was 282 days; in this population, 81% of individuals had chronic skin lesions, a known risk factor for MRSA colonization, which may have contributed to prolonged carriage. Besides host factors, factors associated with the pathogen itself as well as the nasal microbiota can influence host carrier status.
Dynamics of colonization.
During S. aureus colonization, initial bacterial adherence to the host's epithelial cells is mediated by teichoic acid on the cell wall, whereas microbial surface components recognizing adhesive matrix molecules play a part at a later stage of nasal colo niza tion 53, 54 . Of these components, S. aureus clumping factor B (ClfB), has been studied in vitro and in human volunteers 55 . A wild-type strain and its single locus clfB knockout variant were inoculated into the nose; the knockout variant was cleared significantly more rapidly than the wild-type strain. However, ClfBdeficient strains can still interact with nasal cells, indicating that there are several independent microbial surface components that play a part in colonization 56 . It must also be noted that only one strain was used in this study.
Besides host and pathogen factors, the interaction of S. aureus with other nasal-colonizing species (for example, Corynebacterium spp., Propionibacterium acnes, Staphylococcus lugdunensis and Staphylococcus epider midis) has a role in S. aureus colonization. Studies of the nasal microbiota have shown that the presence of some species correlates with the presence or absence of S. aureus (for example, S. epidermidis has been positively correlated with the presence of S. aureus) 57, 58 . The organisms of the nasal microbiota are in competition with each other in several ways. For example, they compete for adhesion sites and nutrients: there are low amounts of nutrients in the human nose. S. aureus can survive in environments with lower levels of nutrients than coagulase-negative staphylococci can 59 , possibly owing to differences in metabolism, and hence is better adapted to the human nose. However, no difference in nutrient levels has been observed between carriers and non-carriers 59 . Microbiota species also compete by antibiosis, that is, certain strains can produce antimicrobial molecules that inhibit their microbial competitors. S. lugdunensis, for example, produces an antimicrobial compound called lugdunin that inhibits and destroys S. aureus (including MRSA) in vitro and in a mouse model, possibly by leading to rapid breakdown of bacterial energy resources 60 . In humans, nasal colonization with S. lugdunensis has been associated with a sixfold lower risk of colonization with S. aureus. These findings are certainly interesting but explain only a minority of carriage patterns, as S. lugdunensis colonization has been reported in only 9 − 26% of the general population 60, 61 . Finally, S. aureus also competes by induction of host defences, that is, it induces the production of host antimicrobial proteins that are less harmful to S. aureus than to other commensal bacteria 62 . Many studies support the role of these mechanisms in the interactions between S. aureus and the commensal microbiota, but a single mechanism is insufficient to explain all observed carriage patterns. 
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, Oxford University Press. 67 . This section focuses on the most prominent virulence mechanisms and typical routes of invasion.
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Initiation of infection. S. aureus
SSTIs are usually initiated by bacterial transfer (probably via hand contact) from the major reservoir in the nose to open microlesions and wounds on the skin 68, 69 (FIG. 4a) . S. aureus surface proteins (for example, fibronectin-binding protein A (FnBPA), FnBPB, clumping factor A (ClfA), ClfB and collagen adhesin (Cna)) bind to extracellular matrix proteins and enable the bacteria to attach to and multiply on wounded tissues 70 . The capacity of S. aureus to adhere to and form biofilms (that is, sticky agglomerations of microorganisms embedded in an extracellular matrix; biofilms facilitate resistance to mechanical interference, host defences and antibiotic treatment) on artificial plastic or metal surfaces renders S. aureus a frequent cause of catheter-associated or joint-replacement-associated infections or of ventilator-associated pneumonia 71 . The subsequent influx of polymorphonuclear leukocytes (PMNs) is manipulated by S. aureus 72 , which shapes local inflammation 73 .
Abscess formation. The S. aureus coagulase proteins cause the formation of a fibrin pseudo-capsule surrounding bacteria and infiltrated PMNs, thereby preventing further leukocyte influx 74 (FIG. 4b) . S. aureus can impede opsonization, for instance, by production of a polysaccharide microcapsule 66 and inhibition of the complement cascade 75 . However, the micro capsule is absent from important MRSA clones such as USA300 (REF. 63 ).
Bacteria that are phagocytosed by PMNs can survive not only by counteracting PMN killing mechanisms 72, 76, 77 but also by gradually destroying them with the help of cytolytic toxins. For example, many CA-MRSA clones produce pore-forming peptide (phenol soluble modulins (PSMs)) and protein toxins (α-toxin (also known as α-haemolysin) and several bi-component leukocidins such as the Panton-Valentine leukocidin (PVL)), which are host species-specific and bind to host leukocyte membranes, leading to the formation of pores and causing lytic cell death 7, 78 , thereby increasing bacterial virulence. The massive inflam mation elicited by activated or necrotic PMNs is further increased by S. aureus super antigen toxins, which bind to the major histo compatibility complex (MHC) class II of antigenpresenting cells and activate a large percentage of T cells non specifically, causing systemic hyper-inflammation referred to as 'cytokine storms' 79 . Systemic infection. Abscesses might be disrupted at later stages, releasing pus and live bacteria either towards the skin surface to promote pathogen transmission or towards the bloodstream to cause bacteraemia (FIG. 4c) . Endovascular S. aureus can adhere to endothelial surfaces and platelets 80, 81 , and this adhesion can initiate endocarditis, promote the formation of metastatic abscesses or induce bacterial uptake into endothelial cells, where the bacteria are difficult to reach by antibiotics and host defence molecules 82 . The agglutinating activity of coagulases is thought to contribute to systemic blood coagulation, and massive release of microorganism-associated molecular pattern mol ecules along with superantigen toxin-induced cytokine storms leads to fulmin ant systemic inflammation, sepsis and multi-organ failure if the endovascular spread of the bacteria cannot be contained 83 .
Regulation and adaptation. Most of the S. aureus virulence factors are differentially regulated by the accessory gene regulator (Agr) quorum-sensing system and other regulatory networks 84 . Many CA-MRSA clones such as USA300 have very active Agr systems, which leads to abundant expression of toxins and corresponds to a high capacity to cause SSTIs and invasive infections even in healthy individuals 85 . By contrast, many HA-MRSA clones contain an additional SCCmecencoded phenol-soluble modulin (PSM; PSMmec), whose mRNA dampens Agr expression 86 . Accordingly, Agr is not very active in many HA-MRSA clones, which produce lower amounts of toxins but higher levels of adhesins and often cause bacteraemia via infected catheters or implanted medical devices. High virulence seems to even be detrimental for S. aureus in bacteraemia, with many isolates from bloodstream infections found to bear Agr-inactivating point mutations 87 . Elucidating virulence mechanisms whose inhibition would render S. aureus most vulnerable will be crucial for the development of new preventive and therapeutic strategies against MRSA.
Mechanisms of methicillin resistance
A crucial event in the evolution of S. aureus was the independent acquisition of the SCCmec complex in the early 1960s by several multidrug-resistant strains (resistant to penicillin, streptomycin, tetracycline and erythromycin 88 ), rendering S. aureus resistant to most members of the β-lactam family of antibiotics 5 (FIG. 3) . Twelve known SCCmec types (I-XII) have been identified and are classified according to the type of cassette chromosome recombinase (ccr) complex and the class of the mec complex (TABLE 2) . Types I, II and III are large SCCmec elements harbouring genes that confer resistance to . PSM peptides also promote the release of pro-inflammatory lipoproteins, the major S. aureus microorganism-associated molecular pattern (MAMP) molecules, which activate Toll-like receptor 2 (TLR2) and contribute to local inflammation 73 . b | S. aureus produces coagulases to polymerize fibrin and form an encapsulated abscess around the infection site. The capacity of PMNs, which are found in high numbers in an abscess, to eliminate S. aureus is limited by leukocidins and by virulence factors interfering with opsonophagocytosis and PMN killing. S. aureus can compromise effective opsonization by antibodies using a polysaccharide microcapsule and surface proteins (Staphylococcus protein A (SpA) and immunoglobulin-binding protein Sbi) binding immunoglobulin G (IgG) via the crystallizable fragment (Fc) domain in a futile way 66 . The bacteria can also inhibit the complement signalling pathway by small secreted inhibitors such as staphylococcal complement inhibitor (SCIN), fibrinogenbinding protein (Efb), extracellular complement-binding protein (Ecb) or staphylococcal superantigen-like protein 7 (SSL7), among others. Phago cytosed bacteria can survive within the PMNs by producing catalase, superoxide dismutase [Mn] 1 (SodA), staphylococcal peroxidase inhibitor (SPIN), staphyloxanthin (against the bactericidal oxidative burst generated by the PMNs) 72 and extracellular adherence protein (Eap) (against elastase) 76 , and the cell envelope modifications mediated by multiple peptide resistance factor (MprF) and the d-alanine transfer proteins DltA, DltB, DltC and DltD protect against defensins. S. aureus also secretes cytolytic toxins that can kill PMNs; S. aureus leukocidins include large pore-forming proteins (α-toxin and several two-component leukocidins, such as Panton-Valentine leukocidin (PVL)) 64 and small peptide (PSM peptides) 228 toxins. Superantigen toxins (toxic shock syndrome toxin 1 (TSST1), enterotoxin type A (SEA), staphylococcal enterotoxin-like X (SEIX) and several others) contribute to exuberant inflammation by nonspecific T cell activation. c | Abscesses can release live bacteria to the surface of the skin and/or the bloodstream at later stages; the plasminogen-activating protein staphylokinase might contribute to bacterial dissemination. APC, antigen-presenting cell. . Smaller elements, such as types IV and V SCCmec, are found in CA-MRSA, such as USA300 and USA400, but also in some widespread HA-MRSA clones, such as ST22-MRSA-IV, ST45-MRSA-IV and ST5-MRSA-VI (FIG. 3; TABLE 2 ). However, over the years, the distinction between the two epidemiological groups (HA-MRSA and CA-MRSA) has become blurred 90 . All SCCmec types contain mecA (with the exception of type XI, which contains the homologue mecC), which encodes penicillin-binding protein 2a (PBP2a) 91 , a peptido glycan transpeptidase. PBP2a has extremely low affinity for most β-lactam antibiotics; in the presence of β-lactam antibiotics that inhibit the function of the four native S. aureus penicillin-binding proteins (PBP1, PBP2, PPB3 and PBP4), PBP2a can take over the transpeptidase function of peptidoglycan biosynthesis (FIG. 5) . A variant of mecA, named mecC, was identified in several S. aureus clones from animal and human isolates 92 ; mecC encodes PBP2a LGA , named after the MRSA strain LGA251 from which it was first isolated. The mechanism of the control of β-lactam resistance in strain LGA251 was compared with the resistance mechanism in MRSA strains that carry mecA 93, 94 ; in the LGA251 strain, the level of methicillin resistance depends on mecC and on genes in the genetic background of the strain. In 2018, plasmid-borne methicillin resistance based on mecB has been identified in S. aureus 95 , but the mechanism of resistance encoded by mecB is yet to be clarified.
The primary control of the expression of mecA depends on the regulators encoded by mecI, mecR1 and mecR2 (REFS 96, 97 ) and on the regulators of the expression of the genes blaZ, blaI and blaRI (REF. 98 ). In addition, a surprisingly large number of genes -auxiliary or fem genes -has a profound influence on the resistant phenotype 99 . Three lines of evidence show that the level of mecA transcription is not predictive of the degree of methicillin resistance. First, the stringent stress response (that is, the bacterial reaction to different stress conditions, such as amino acid, fatty acid and iron limitation and heat shock) induced by the antibiotic mupirocin triggers an increase in PBP2a activity without affecting mecA transcription 100 . Second, inactivation of vraS (a member of the two-component regulatory system involving sensor protein VraS and response regulator protein VraR (VraS-VraR) involved in the control of the cell wall peptidoglycan biosynthesis) induced mecA transcription but did not increase the level of PBP2a activity 101 . Third, the chaperone foldase protein PrsA alters the levels of properly folded PBP2a in the membrane and, therefore, methicillin resistance without affecting mecA transcription 102 . The crucial role of the stringent stress response in mecA expression has been demonstrated using different experimental approaches 99, 103 . A new line of investigation is focusing on the discovery of inhibitors of the stringent stress response that act in combination with β-lactam antibiotics 103 . Of note, over the years, some MRSA clones have also acquired resistance to vancomycin 104 , the first-line treatment of invasive MRSA infections in hospitalized patients since the 1960s
Diagnosis, screening and prevention MRSA can cause a wide range of infections, such as SSTIs, pneumonia, osteoarticular infections, toxic shock syndrome (a rare, potentially life-threatening complication of infection with certain types of bacteria, including S. aureus, caused by the release of bacterial toxins and presenting with clinical features that can include fever, rash and hypotension) and bacteraemia, which may be complicated by endocarditis or severe sepsis 4 . The clinical presentations and risk factors for infection vary between HA-MRSA, CA-MRSA and LA-MRSA strains.
HA-MRSA
HA-MRSA is a cause of bacteraemia, pneumonia and, less commonly, SSTIs (particularly related to invasive procedures, for example, at surgical wounds or vascular access sites) in hospitalized patients 105 . The organism is often associated with invasive devices, such as intravascular catheters, endotracheal tubes and urinary catheters, probably owing to its capacity to form and survive in biofilms 71 . Individuals who have had lengthy hospitalization, ICU admission, residency in a nursing home, antibiotic exposure (particularly to cephalosporins and fluoroquinolones, leading to antibiotic selection pressure), surgery, haemodialysis, chronic wounds or indwelling invasive devices have an increased risk of infection with HA-MRSA 106 . In addition, asymptomatic colonization with MRSA is a risk factor for subsequent infection, as individuals with MRSA colonization on admission had a relative risk of infection of 13 (95% CI 2.7-64.0) compared with those with MSSA colonization or 9.5 (95% CI 3.6-25.0) compared with those without S. aureus colonization 107 . 
CA-MRSA
The most common clinical presentation for CA-MRSA is SSTI, which is often associated with abscesses or pus formation and accounts for ~90% of cases 29 . CA-MRSA can cause particularly virulent infections. Fulminant infections with CA-MRSA strains have been reported, such as necrotizing pneumonia and necrotizing fasciitis (a rapidly progressive infection of the fascia with secondary necrosis of the subcutaneous tissues) 108, 109 . Possible explanations for the increased virulence observed with CA-MRSA strains are very active Agr systems and the production of PVL. However, the presence of PVL varies from strain to strain, suggesting that other virulence factors contribute 7 . Individuals with CA-MRSA infection usually lack the traditional risk factors associated with HA-MRSA strains. Populations or settings in which outbreaks of CA-MRSA infection have been reported include sports teams, mili tary personnel and prisons 110, 111 . On the basis of these observations, close contact with MRSA carriers (as occurs in households or other communal living environ ments), shared equipment or personal items and skin trauma (including trauma caused by injecting drug use or body shaving) might be associated with an increased risk of CA-MRSA infection. However, the distinction between CA-MRSA and HA-MRSA is becoming increasingly blurred, with transmission of CA-MRSA strains now being observed in health-care settings in some countries with high CA-MRSA burden, such as Greece 112 .
LA-MRSA
LA-MRSA has been associated with localized infections, such as SSTIs (including abscesses and wound infections) and otitis, as well as severe and invasive infections, such as bacteraemia, pneumonia, osteoarticular infections and endocarditis 22 . LA-MRSA predominantly colonizes and infects individuals who have direct contact with livestock (including cattle, horses, chickens and turkeys but particularly pigs) and their household members through transmission within the household 25 . However, there are reports of LA-MRSA in individuals with no connection to livestock, and in these cases, spread via environmental contamination or, less commonly, food-borne transmission has been postulated 25 .
Microbiological diagnosis
Microbiological specimens from which MRSA can be isolated can be broadly classified into clinical and screening samples. Clinical samples (for example, specimens of purulent discharge, deep tissues, sputum and blood) are collected from individuals with symptoms or signs to investigate for active infection, whereas screening samples (for example, nasal, perineal and throat swabs) are obtained to detect asymptomatic colonization. An array of phenotypic and non-phenotypic methods can be used to detect MRSA directly from clinical or screening samples or to identify MRSA from presumptive staphylo coccal colonies isolated from clinical samples. Phenotypic methods are usually preferred for clinical diagnostics. 113 . Initially, oxacillin was utilized as the marker antibiotic to detect MRSA; however, CLSI now recommends cefoxitin, as it is a better inducer of mecA and mecC than oxacillin and results in a clear recognizable phenotype 113 . The disk-diffusion method requires strict adherence to temperature (35 °C) and time (reading after 24 hours) to prevent false negative results. This is because the mecA encoded PBP2a is less efficient at crosslinking the pentapeptide chains of the cell wall peptidoglycan during cell wall synthesis, resulting in slower growth of the resistant isolates. This phenomenon leads to a heteroresistant population, wherein cells exhibit different levels of resistance and some are phenotypically susceptible 114 . The above-mentioned susceptibility testing guidelines enable the slower growing MRSA subpopulation to reach detectable levels in a heteroresistant population. Rarely, MRSA may present with phenotypic sensitivity to cefoxitin (and oxacillin) and require an overnight exposure to low concentrations of cefoxitin to exhibit resistance 115 . In this case, the presence of inducible mecA should be considered. Methicillin resistance in S. aureus colonies and cultures can also be detected by means of an antigen-antibodybased latex agglutination test that detects PBP2a by using an anti-PBP2a antibody. Moreover, several automated instruments performing identification and antimicrobial susceptibility testing of staphylococci have shown high sensitivities and specificities for the MRSA strains tested (reviewed in REF.
116
).
For Non-phenotypic methods. One of the most promising non-genotypic techniques for direct identification of pathogens from positive blood cultures is matrixassisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-TOF MS) 118 . Identification is based on the comparison of the protein profile obtained by mass spectrometry from a bacterial or fungal sample with a database of profiles obtained from several character ized microorganisms. However, as the performance of MALDI-TOF MS largely depends on a microorganism's purity and quantity, bacterial enrichment and purification procedures are required from positive blood cultures, which contain high concentrations of interfering non-microbial material 118 . A retrospective study of 227 cases of S. aureus bacteraemia comparing turnaround time and therapy adjustment before and after the introduction of MALDI-TOF MS plus real-time PCR to detect mecA showed a decrease in turnaround time of MRSA identification by nearly 50% compared with S. aureus identification and β-lactam susceptibility testing by conventional methods. Although the length of hospitalization and rates of adequate empirical anti bacterial therapy were similar in the two groups, optimiza tion of therapy occurred more frequently in the group assessed by MALDI-TOF MS 119 . Current DNA-based methods for direct MRSA detection from clinical samples are multiplex real-time PCR assays to detect S. aureus and the presence of mecA 120 and are well-validated assays 121 . Results are obtained in approximately 1.5 hours. The FilmArray (Idaho Technology, Salt Lake City, Utah, USA) is a multiplex PCR-based system designed to detect 25 microorganisms (90-95% of the pathogens involved in blood cultures) along with mecA, as well as the presence of genes encoding resistance to vancomycin (vanA and vanB) and carbapenems (bla KPC ) 122 . This assay has higher sensitivity than MALDI-TOF MS in identifying microorganisms from blood culture bottles before positivity, with an average turnaround time of 2.5 hours 123 . The application of WGS to bacterial pathogens heralded the single most important advance in diagnostic microbiology and surveillance since in vitro culture. However, direct applications of WGS in diagnostic ), and since then, it has been identified worldwide. The VISA phenotype results from mutations acquired during antibiotic therapy 216 . Despite its low vancomycin minimum inhibitory concentration (MIC; the lowest concentration of an antibiotic that prevents bacterial growth) of 3-8 micrograms per millilitre, VISA has been associated with treatment failures 215 . When cultured, heterogeneous VISA (hVISA) strains are phenotypically susceptible to vancomycin but contain subpopulations of VISA colonies at frequencies of 10 −6 to 10 −5 of the cells in the whole population. hVISA seems to be the stage that precedes the development of VISA 217 . The clinical relevance of hVISA has been extensively debated. Vancomycin failure has been reported for some hVISA or VISA infections; nevertheless, several studies have failed to detect an association between infection with hVISA and poor outcomes with therapy with vancomycin 218, 219 . For specific cases of hVISA and/or VISA infection, viable alternatives to vancomycin include a combination of high-dose daptomycin with another antibiotic such as gentamicin, rifampin, linezolid, trimethoprim-sulfamethoxazole or a β-lactam. Similarly, if reduced susceptibility to daptomycin is observed alongside reduced vancomycin susceptibility, then a combination of or use of a single agent among the following is recommended: quinupristin-dalfopristin, trimethoprim-sulfamethoxazole, linezolid or telavancin 161 . Vancomycin-resistant S. aureus (VRSA), which was first detected in the United States in 2002 (REF.
220
), has a very high vancomycin MIC (≥32 micrograms per millilitre). Vancomycin resistance in VRSA is mediated by the vanA gene, which is believed to have been transferred from Enterococcus faecalis on the plasmid-borne transposon Tn1546 (REF.
221
). VRSA strains are mostly found in diabetic wounds infected by both vancomycinresistant enterococci and S. aureus, where there is opportunity for horizontal gene transfer of Tn1546 harbouring vanA. VRSA has remained extremely rare, possibly owing to the fitness costs associated with acquisition of vancomycin resistance 222 . microbiology remain limited, primarily because of the technological constraints in obtaining results within a time frame that can influence patient care and the need for standardized protocols and automated data interpretation. The introduction of the third generation of sequencers (such as the Oxford Nanopore MinION by Pacific BioSciences and Oxford Nanopore, Oxford, UK) has resulted in longer reads (obtained sequence lengths) that can span repeat regions in the bacterial sequence and enable complete bacterial genome assembly, as well as an increased portability of the machinery and a potential reduction in error rates. An important benefit afforded by the Oxford Nanopore MinION sequencer is that sequencing data can be analysed in real time and could lead to strain identification within 30 min and an antibioticresistance profile prediction within 10 hours after the start of a run 124 , making this assay potentially useful for clinical diagnostics. The utility of WGS has been well demonstrated for studying antibiotic resistance and the population biology of MRSA 125 and has also led to many useful insights regarding transmission of MRSA during hospital outbreaks 126 and in community settings 127 .
Screening methods
Screening measures and their effectiveness are discussed in the Prevention section below. Since the introduction of the first MRSA chromogenic medium (that is, a medium containing synthetic chromogenic enzyme substrates; in the presence of the specific target enzyme, the chromogenic substrate is processed and results in a corresponding bacterial colony of a specific colour, thereby enabling pathogen recognition) 128 , these media have undergone rapid improvements in terms of sensitivity of the chromo gen and the antibiotics used 120, 129 . They have become the primary rapid diagnostic assays utilized for active surveillance for MRSA colonization as well as for patient diagnostics since they were introduced in the 2000s 129 . In 2005, an external quality assessment in 23 European countries and Israel found that 88% of the participating laboratories utilized a chromogenic medium alone to screen for MRSA 130 . The combination of chromogenic media with MALDI-TOF MS, which enables the species identification of multiple colonies in <1 hour, has further improved the speci ficity and turn around time 131 . Development of automated colony scoring that could further increase specificity and reduce turnaround time is also being attempted 132 . Application of real-time PCR-based assays for MRSA screening from nasal swabs can decrease turnaround time to 1-2 hours, whereas the results of chromogenic mediabased tests can take a minimum of 14-18 hours without confirmatory testing and, therefore, might not always be useful to guide clinical decisions. An observational cohort study demonstrated a significant reduction in MRSA transmission upon screening with a same-day commercial real-time PCR assay compared with screening with conventional culture (swabs incubated overnight in 7% NaCl and subcultured on mannitol salt agar with 2 milligrams per litre oxacillin for 48 hours): MRSA transmission was 4.9 new acquisitions per 1,000 patient bed days with real-time PCR compared with 13.9 new acquisitions per 1,000 patient bed days with culture 133 . (A patient bed day represents a unit of time during which a patient occupies a bed and stays overnight in a health-care facility; thus, 50 patients in a hospital over a period of 1 day would represent 50 patient bed days.) However, a major study in 13 ICUs in eight European countries did not find any positive effect of screening using PCR-based tests versus chromogenic media in the acquisition and transmission rates of multidrug-resistant bacteria (including MRSA, vancomycin-resistant enterococci and highly-resistant Enterobacteriaceae) 134 . Similarly, a UK-based study assessing screening by real-time PCR-based tests versus slower laboratory-based methods (MRSA-selective broth and chromogenic medium) reported a significant reduction in turnaround times (from 40.4 to 3.7 hours) but again no effect on MRSA acquisition rates 135 , thereby rendering the utility of the more-expensive albeit faster PCR-based screening questionable.
Prevention
MRSA control interventions have been widely implemented across health-care facilities. These interventions aim to limit the emergence of MRSA by facilitating judicious use of antimicrobial agents (including introducing restrictions on their prescription), control the reservoir of patients who are carriers, prevent MRSA transmission between patients and prevent the development of infection in carriers. Several measures are usually required to successfully prevent transmission and infection with MRSA 136 . Decolonization, an important control intervention for which there is growing evidence, is discussed in the Management section.
Hand hygiene. By contact with patients with MRSA colonization or handling MRSA-contaminated equipment, health-care workers can acquire MRSA on their hands, and by this means, MRSA can be transmitted between patients 137 . Hand hygiene, with alcohol-based hand rub or soap and water, aims to reduce MRSA spread via this route. Indeed, the WHO has identified hand hygiene as an important factor in providing safe patient care and has issued detailed instructions regarding appropriate hand hygiene practices among health-care workers 137, 138 . The effectiveness of improving compliance with hand hygiene among health-care workers in MRSA control has been demonstrated at local as well as national levels 139, 140 . For example, the roll out of a national hand hygiene programme in England and Wales from late 2004 was associated with a fall in the incidence of MRSA bacteraemia from 1.88 to 0.91 per 10,000 patient bed days 140 . Although the hand hygiene campaign was implemented with other national infection control initiatives, the higher procurement of alcohol hand rub during the campaign was independently associated with reduction in the incidence of MRSA bacteraemia after adjustment for all other interventions 140 
.
Active surveillance. Most patients with MRSA colonization are asymptomatic, and, therefore, relying on culture of clinical samples (which are collected only when an individual develops symptoms or signs of infection) alone to identify carriers of MRSA may fail to identify up to 85% of individuals with MRSA colonization 141 . Through screening methods, active surveillance programmes can identify this large asymptomatic reservoir of carriers and direct interventions (such as topical decolonization) to reduce transmission or infection risk. MRSA screening may be universal (applied to all patients) or targeted (limited to patients at increased risk of MRSA carriage). Universal MRSA screening has been one of the most controversial areas in infection control since the 2000s, with some studies showing that it is effective in reducing MRSA-associated disease 142 , whereas other studies found it ineffective 143, 144 . Importantly, recent data also show that universal screening is unlikely to be cost-effective, particularly in settings with low or decreasing MRSA prevalence 145 . On the basis of this accumulating evidence, many health-care facilities have now abandoned universal MRSA screening. We suggest, however, that changes in practices should be based on careful consideration of local MRSA epidemiology and the vulnerability of the patient population.
Randomized trials in ICUs have questioned the utility of routine MRSA screening in this high-risk setting 146, 147 . However, a long turnaround time for screening results (a mean of 5.2 days with a culture-based method using a pre-enrichment step at a central laboratory) 146 or established good hand hygiene practices coupled with universal chlorhexidine bathing 147 might have contributed to the observed lack of effect of screening. It is argued that 'horizontal' strategies (that is, strategies aimed at preventing all health-care-associated infections, including MRSA, such as hand hygiene and universal bathing with antiseptics) are a better use of limited resources.
Contact precautions and isolation. In many facilities, health-care workers use contact precautions (use of disposable gowns and gloves) when caring for patients with MRSA colonization to reduce MRSA transmission associated with contamination of hands and clothing. Although the evidence for this intervention has previously been of low quality, there is now more robust data suggesting that this practice is associated with reduction in MRSA acquisition 148 . It is also widely recom mended that patients with MRSA colonization are isolated in single rooms. However, in a prospective study in an ICU setting where MRSA was endemic and hand hygiene compliance was low, single-room isolation was not effective in reducing MRSA transmission 149 . Experts have called for a review of this practice and for guidelines to highlight the uncertainties regarding its value 150 .
Management
The approach to the management of MRSA varies in different geographical regions depending on local MRSA prevalence and availability of antimicrobials, particularly the newer agents.
Decolonization of carriers
MRSA colonization is associated with an increased risk of infection and contributes to transmission. Both MRSA colonization on admission as well as acquisition during hospitalization are associated with an approximately tenfold increased risk of subsequent infection 107 . Thus, decolonization can contribute to MRSA control by reducing transmission and infection risk. Most decoloniza tion strategies use topical agents applied to the nostrils, the principal site of colonization 47 . Mupirocin (pseudomonic acid A, which inhibits bacterial isoleucyl tRNA synthetase, preventing protein synthesis) is the principal agent and is often combined with chlorhexidine bathing 151 . Although mupirocin is the cornerstone for eradication of S. aureus, resistance is increasing, with some studies reporting resistance rates of up to 80% in MRSA 152 . Alternative agents are being studied, but to date, experience with these agents is limited 153 . Thus, it is recommended that mupirocin is used judiciously and that the emergence of resistance is monitored 152 . Ongoing research into the development and evaluation of new agents that can be effectively used for decolonization is also needed.
Short-term decolonization.
Decolonization is most commonly used as a protective strategy during relatively short periods of increased risk of infection, for example, during the peri-operative period or ICU stays. Topical mupirocin to the nares and chlorhexidine body washing before surgery for known S. aureus carriers reduced the risk of post-surgical S. aureus infection by ~50% in a placebo-controlled study 154 . A subsequent costeffectiveness analysis using these data showed that the mean cost saved per treated carrier was €1,911 (REF.
155
However, this study was performed in the Netherlands, a country with low MRSA prevalence, and the effects of this short-term decolonization strategy might be different in settings with high MRSA prevalence.
The results of short-term decolonization interventions in the ICU setting have been variable. A large cluster-randomized trial compared three strategies 156 : screening and isolation of MRSA carriers (no decoloniza tion); a combination of screening, isolation and decolonization (with mupirocin and chlorhexidine bathing) of MRSA carriers (targeted decolonization); and decolonization of all patients (universal decolonization). No significant differences in MRSA colonization and infection rates were found with the three strategies. However, bloodstream infections from any pathogen were significantly lower in the universal decolonization group. This may have been the result of universal chlorhexidine bathing rather than mupirocin. The authors concluded that universal decolonization was the best approach, as it reduced infections overall without the need for screening. However, as widespread use of topical antibiotics might lead to an increase in drug resistance, their use should be coupled with monitoring for resistance 152 .
Permanent decolonization. In some situations, permanent MRSA eradication is pursued. Permanent decoloniza tion is a component of the 'search and destroy strategy' in countries with a low MRSA prevalence 157 . For example, the Dutch protocol distinguishes between uncomplicated and complicated carriers on the basis of MRSA strain and host characteristics, as well as colonization site, as treatment failure is three times more likely in individuals with throat colonization than in those without throat colonization 158 . Of 613 MRSA carriers, 80% were ultimately successfully decolonized, with a median time to decolonization of 10 days; of note, adherence to the protocol was crucial for success. Many other clinical trials evaluating permanent decolonization strategies have been conducted under real-life conditions, with rather disappointing results because of a high rate of endogenous recolonization 151 .
Treatment of symptomatic infection
Empirical treatment and SSTIs. We recommend that an antibiotic effective against MRSA should be considered for empirical treatment of infection for patients with several risk factors for HA-MRSA infection or those with presumed severe staphylococcal infections in settings where MRSA prevalence is >20%, although precise thresholds have not been established. The choice, route of administration and duration of antibiotic therapy are determined by the site and severity of infection. Treatment should then be adjusted on the basis of subsequent results of cultures and susceptibility testing.
Intravenous vancomycin, daptomycin or linezolid can be used for severe SSTIs. Oral therapy as a rule should be avoided in the initial treatment of severe infections. Clinda mycin, trimethoprim-sulfamethoxazole and doxycycline are alternative choices for the treatment of mild to moderate SSTIs, depending upon the antibiotic susceptibility testing. For uncomplicated skin abscesses, the use of clindamycin or trimethoprim-sulfamethoxazole in conjunction with incision and drainage has been shown to improve clinical cure rates in the emergency department and other outpatient settings 159, 160 . Systemic and severe infections. The current recommendations for clinical management of severe MRSA infections include intravenous vancomycin or daptomycin for bacteraemia and intravenous vancomycin or linezolid for hospital-acquired pneumonia 161 . For severe infections, oral linezolid should not be used for initial therapy. However, when the patient has become stable and can tolerate the oral route, a switch to oral linezolid is recommended. In the setting of infection related to the presence of a medical device (such as central venous catheters), successful treatment usually requires removal of the device when possible 161 . Glycopeptides (such as vancomycin and teicoplanin) have been the mainstay of intravenous treatment for MRSA infections. Vancomycin remains the cornerstone of empirical treatment for systemic infections potentially caused by MRSA, first because of its safety profile and second owing to lack of other fully approved alternatives 161, 162 . Teicoplanin is also commonly used in Europe and has been found to be non-inferior to vancomycin in terms of all-cause mortality, with an improved safety profile, although few patients with serious infections were studied 163 (TABLE 3) . Of note, glycopeptides have slower bactericidal activity than β-lactam agents, and penetration into tissues is poor.
Recommendations have been made to increase vancomycin administration to achieve an appropriate 'trough' concentration (lowest concentration reached by the drug before the next dose is administered) and, in this way, to maximize the chances of microbiological and clinical cure (eradication of the organism as demonstrated by negative cultures and resolution of signs and symptoms of infection, respectively) 161, 164 . Also, optimiza tion of vanco mycin therapy on the basis of pharmacokinetic and pharmacodynamic targets is becoming increasingly relevant, particularly as reports of the incidence of MRSA clinical isolates with min imum inhib itory concentrations (MICs) >1 microgram per milli litre (which is just below the breakpoint) are increasing in several settings. However, higher trough concentrations are associated with an increased risk of nephrotoxicity 165 and no clear improvement in outcome. Finally, vancomycin is administered in a continuous infusion instead of intermittent injections in some European countries 166 . However, there are insufficient data to make recommendations regarding this protocol 166 . In the presence of infections caused by MRSA strains with an MIC higher than the current breakpoint (>2 micrograms per milli litre), vanco mycin is not effective, and an alternative agent should be administered 167 . Switching to dapto mycin therapy, on the basis of the daptomycin MIC, should be done as early as possible once an elevated vancomycin MIC is confirmed. Alternative anti-MRSA anti biotics are increasingly being used, but it is important to note that they can have adverse effects, particularly linezolid 168 (TABLE 3) .
Of note, although reports of vancomycin failure have emerged for vancomycin intermediate-resistant S. aureus (VISA) and/or hetero geneous VISA (hVISA) infections, no data demonstrate superior outcomes with alternative antimicrobials agents
Combination therapy. The duration of bacteraemia in patients with MRSA is twice as long as that in patients with MSSA infection 169 . The increased duration of bacteraemia is associated with complications (such as attributable mortality, complicated infection, embolic stroke or recurrent S. aureus infection) 170 . Combination therapy to treat S. aureus (including MRSA) bacter aemia has been used in an attempt to increase bacterial killing, particularly for endocarditis therapy 171 . However, evidence that combination therapy improves outcomes is lacking 171 . Several studies have demonstrated in vitro synergy between vancomycin and gentamicin against many MRSA isolates 172,173 . However, this combin ation seemed to be numerically inferior to daptomycin alone in the treatment of MRSA bacteraemia and endocarditis in a randomized trial 174 . Thus, because even low dose gentamicin (1 milligram per kilogram every 8 hours) for a short duration has been associated with substantial nephrotoxicity 175 and because the clinical effectiveness of vancomycin plus gentamicin is not confirmed, combination therapy with aminoglycosides is difficult to justify 176 . Vancomycin and rifampicin combinations have also been studied, particularly in the context of biofilm infections 177 . However, the addition of rifampicin to vanco mycin is not recommended for MRSA bacteraemia or native valve endocarditis 161 . In addition, a ran domized controlled trial evaluating adjunctive rifampicin in S. aureus (including MRSA) bacteraemia found no overall benefit 178 .
The combination of vancomycin and β-lactam antibiotics has shown synergistic bacterial killing in vitro 179 . However, sufficient clinical evidence in favour of this combination is lacking. In the CAMERA-1 trial (comparing vancomycin versus vancomycin plus • Non-inferior to vancomycin plus aztreonam for treatment of SSTI 253 flucloxa cillin), the mean time to resolution of bacteraemia (primary outcome) in the combination group was 1.94 days, compared with 3.00 days in the vancomycin alone group. According to a negative binomial model, the mean time to resolution of bacteraemia in the combination group was 65% (95% CI 41-102%; P = 0.06) of that in the group that received intravenous vancomycin alone (that is, it was 35% lower), and there was no difference between the two groups in relation to the secondary end points 179 . Ceftaroline plus daptomycin could be another option for refractory staphylococcal bacteraemia. Ceftaroline offers dual benefit via synergy with daptomycin and sensi tization to cathelicidin antimicrobial peptidederived LL-37, a peptide of the host innate immune response; sensitization to cathelicidin could attenuate the viru lence of the pathogen 180 (see New drugs and current pipeline). Other combinations (for example, daptomycin and rifampicin) might be promising options in biofilm-related infections 181 .
Other considerations. In contrast to many other bacterial infections, S. aureus (including MRSA) infections often require a lengthy course of treatment because of the risk of late-onset complications such as abscesses, osteoarticular infection and other secondary foci caused by haematogenous or direct seeding. In cases of documented bacteraemia, the recommended minimum duration of treatment is 14 days 161 , as short-course therapy is currently not considered to be safe and effective.
Options for salvage therapy, based on low-quality data, include linezolid, trimethoprim-sulfamethoxazole, ceftaroline, quinupristin-dalfopristin and telavancin. Tigecycline should be avoided, as it is bacteriostatic against MRSA and has a large volume of distribution with high concentrations in tissues but low concentrations in serum 161 . No data in MRSA bacteraemia are yet available for other recently approved agents (for example, ceftobiprole, dalbavancin, oritavancin or tedizolid).
New drugs and current pipeline
Several new agents have been approved for the treatment of SSTIs and in some cases for pneumonia (FIG. 5; TABLE 4) . However, the efficacy and safety of these antibiotics for invasive infections, for which there is a real need, have largely not been demonstrated. The new treatment options have some advantages over older agents and will probably play a part in the therapy of severe MRSA infections in the near future.
Ceftaroline and ceftobiprole are the first β-lactams with anti-MRSA activity. Use of the combination of daptomycin with an anti-staphylococcal β-lactam for refractory MRSA infections has been increasing. Multiple case reports have now documented success of the dapto mycin-ceftaroline combination for MRSA bacteraemia and endocarditis 182 . Ceftobiprole for endocarditis has been studied in animal models only, with promising results 183 , with a single human case report of ceftobiprole plus daptomycin for MRSA endocarditis 184 . However, resistance to ceftaroline has been observed in MRSA strains 185, 186 . Of particular concern are reports of resistance in clinical MRSA isolates from patients in geographical regions never exposed to the drug 187 . Teicoplanin, introduced in Europe in 1988, was the first natural agent of the lipoglycopeptides class. Synthetic and semisynthetic derivatives of lipoglycopeptides have been produced, including telavancin in 2009 and dalbavancin and oritavancin in 2014 (REF. 188 ). In 10 years of dalbavancin surveillance testing, only 0.35% of S. aureus isolates exceeded the FDA susceptibility breakpoint and, therefore, were dalbavancin nonsusceptible 189 . However, the long half-life of dalbavancin could lead to prolonged periods of low-level drug exposure at the end of therapy, potentially increasing the risk of resistance selection 190 . Possible advantages of tedizolid over linezolid include once-daily dosing, better adverse effects profile and lower risk of development of spontaneous resistance and susceptibility to the ribosomal RNA large subunit methyltransferase Cfr mobile resistance mechanism. As experience increases, tedizolid may be an attractive alternative for long-term treatment of osteoarticular and central nervous system infections. Trials in pneumonia are underway.
Ceftaroline, ceftobiprole, telavancin, dalbavancin and delafloxacin all require renal dose adjustment (that is, the antibiotic dose requires modification in individuals with impaired renal function).
Quality of life
Clinical effect MRSA infections frequently complicate medical care and cause important treatment challenges. Most experts agree that β-lactam antibiotics are the optimal choice for treating invasive staphylococcal infections 171 . Thus, MRSA treatment relies on less efficacious (vancomycin) or more expensive (daptomycin or linezolid) therapeutic options. Owing to important prognostic cofactors such as potentially inadequate treatment, patient comorbidities and underlying illness, MRSA infections tend to have higher morbidity and mortality than MSSA infections 191 . However, the true clinical effect of methicillin resistance in S. aureus infection has been overestimated owing to methodological shortcomings of studies 192 . More-recent studies using advanced analytical approaches accounting for potential confounders and competing events confirm a non-negligible effect, which is, however, less pronounced than previously hypothesized 193, 194 . For instance, a large international retrospective cohort study in ten European hospitals with endemic MRSA reported that methicillin resistance in S. aureus bacteraemia was not significantly associated with increased probability of in-hospital mortality (adjusted HR 1.26; 95% CI 0.82-1.94) after adjusting for potential confounders and accounting for the timing of events 195 . In this study, both MSSA and MRSA bacteraemia led to prolonged length of hospital stay, with a nonsignificant difference of 2.5 days (95% CI -3.2 to 8.3) longer for patients with MRSA infection.
Among patients with bacteraemia caused by S. aureus, methicillin resistance is associated with adverse health outcomes. Several studies show that patients with invasive MRSA infection might have diminished probability of long-term survival, regardless of the adequacy of initial treatment 191, 196 . Furthermore, patients with MRSA infection can experience post-infection sequelae (such as the requirement for amputation owing to the higher risk of treatment failure for MRSA infections of prosthetic joints) and harmful adverse effects related to MRSA treatment 197, 198 . Family members might be overwhelmed with caring for patients with MRSA infection in the community 199 . By contrast, MRSA carriage may not cause major concern per se, as shown in a Dutch study in which health-related quality of life was not decreased in otherwise healthy pig farmers carrying LA-MRSA 200 .
Burden of disease
MRSA infections add to the global burden of antibiotic resistance. Several studies have shown that increased incidence of HA-MRSA infection occurs in addition to infections caused by MSSA, increasing the total burden of disease 201 . Furthermore, once endemic levels of MRSA are reached in a clinical setting, physicians are required to treat patients empirically for MRSA in cases of severe nosocomial infection 161 . This probabilistic approach of adding vancomycin or linezolid to empiric anti biotic coverage might be continued for years, even after MRSA incidence has substantially declined 202 . Finally, MRSA control requires substantial infrastructure and productivity costs of surveillance, screening and isolation of MRSA carriers 203 . However, these MRSA control expenditures (for example, universal, nation-wide MRSA screening) may no longer be justified once MRSA prevalence has declined below specific thresholds 145 .
Outlook
Vaccines
The development of a vaccine could have an enormous effect on the incidence and outcome of MRSA infections. Indeed, S. aureus carriers have more frequent infections, but the infections are less severe than those developed by non-carriers 204 , indicating that long-term exposure to S. aureus antigens can lead to protective • Whole-genome sequencing (WGS): effectiveness studies on WGS usefulness for clinical diagnostics and rapid antibiotic susceptibility testing • Biomarkers: rapid molecular diagnostic tools and biomarkers for individual risk-profiling and treatment approaches • MRSA reservoirs in animals: determinants of MRSA host tropism and host jumps immunity. A vaccine could prevent infections at the onset and would ideally also impair S. aureus colonization, thereby strongly reducing the need for antibiotic treatment and extensive infection control measures 205 . Therapeutic monoclonal antibodies such as the passive vaccine against α-haemolysin by Medimmune (Gaithersburg, Maryland, USA) could provide new treatment opportunities, either alone or in combination with antibiotics. However, despite extensive research and development efforts, a protective vaccine against S. aureus will not become available in the next few years.
Two monovalent vaccine candidates have previously been tested but failed to induce protective immunity in late clinical development. The StaphVax vaccine (Nabi Bio pharmaceuticals, Rockville, Maryland, USA), containing the capsular polysaccharide 5 (CP5) and CP8 antigens, and the V710 (Merck, Kenilworth, New Jersey, USA) vaccine, containing the iron-regulated surface determinant protein B (IsdB) antigen, have been protective in animal models but not in placebo-controlled phase III trials 206, 207 . The reasons for failure remain unclear but may be related to the fact that several important S. aureus clones, including the major MRSA clone USA300, do not express any CPs, that the antigen prepar ations lacked adjuvants and that immune responses to the antigens used were not consistent enough. Moreover, there is a general concern that the extensive set of S. aureus immune evasion factors, such as immuno globulin G (IgG)-binding protein A, could compromise the efficacy of antibodies, that opsonizing antibodies might not be sufficient to promote protection, whereas toxin-neutralizing antibodies might be equally or even more important, and that appropriate T cell-mediated immunity might be more crucial than previously thought 208 .
Advances from basic science provide cues for new and hopefully more-successful vaccination approaches. Immunoproteomics studies have helped to elucidate the most immunogenic and protective S. aureus antigens 209 , and the cell wall glycopolymer wall teichoic acid (WTA) has been identified as a dominant surface antigen 210 . Several new toxins, whose neutralization by antibodies might contribute to protection, have been identified 64 . Moreover, it has become clearer which T cell subsets are required for anti-S. aureus immunity 211 . Pharmaceutical companies continue to develop polyvalent anti-S. aureus vaccines based on surface proteins (ClfA) and polysaccharides (CP5 and CP8), secreted toxins (α-toxin, LukS-PV, ESAT-6 secretion system extracellular protein A (EsxA) and EsxB) and membrane-bound lipoproteins involved in nutrient uptake (manganese transport system membrane protein MntC and ferric hydroxamate receptor 2 (Fhud2)) 205 . An innovative WTA-targeting monoclonal antibody conjugated to a rifampicin-related antibiotic showed protection in preclinical infection models 212 . There is hope that some of the ongoing vaccine development efforts may lead to successful completion of clinical trials.
Research needs and priorities MRSA will probably always coexist with humanity. Despite the current focus on multidrug-resistant Gram-negative bacteria and the decline of HA-MRSA infections in some regions, the biomedical research community would be well advised not to abandon its diverse activities in the field of MRSA research. As highlighted by a 2017 WHO report 213 , MRSA remains among the high-priority multidrug-resistant organisms that need renewed efforts for the research and development of new antibiotics and innovative preventive approaches. In addition to protective vaccines, bacteriophages or bacteriophage-derived lytic proteins could be used for new protective strategies, for instance, for nasal MRSA decolonization in an era of increasing mupirocin resistance 214 . Overall, there are still many knowledge gaps and important challenges to tackle
, which require ongoing attention from researchers, policy makers and funders as well as those responsible for MRSA treatment and control.
MRSA has demonstrated its remarkable ability to evolve and disseminate widely in the 60 years since it was first recognized. Several factors, including a better understanding of the pathogenesis of infection, accurate and rapid diagnostics, ensuring the availability of effective treatment options and optimization of the prevention of transmission and infection, will ultimately facilitate control of this highly successful pathogen.
